Immunovia AB (Nasdaq: IMMNOV) (Stockholm: IMMNOV) today announced that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer. This will enable increased R&D productivity for Immunovia as the Company continues to strengthen its commercial development in the US.
The partnership between Immunovia and Proteomedix leverages the companies’ complementary R&D capabilities and advances their R&D efforts. With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and will focus internal resources on the commercial build up, thus further accelerating the roll-out of IMMray™ PanCan-d. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics, who have both launched innovative oncology tests, Immunovia with IMMray™ PanCan-d in the U.S. and Proteomedix with Proclarix® in Europe.
Proteomedix, a Swiss-based Company, was founded 2010 as a spin-off company of ETH Zurich to bring together the expertise of a multi-disciplinary group of world-leading scientists and clinicians in proteomic-based diagnostics. The Company is focused on research and development that relies on a network of clinicians, IVD experts, laboratories, and marketers. Proteomedix has developed a blood-based prostate cancer test using proteomics technology that measures cancer-associated proteins, using highly reproducible immunoassays.
“We are very excited to enter this partnership with Immunovia, an early-commercial company like us with an innovative diagnostic test in oncology. This partnership enables both companies to faster take critical steps forward by leveraging our combined expertise to increase R&D efficiency. For Proteomedix, this partnership demonstrates how our biomarker assay development expertise can be deployed beyond prostate cancer,” said Helge Lubenow – CEO, Proteomedix.
“Immunovia is entering a new phase with an increased focus on the commercialization of our IMMray™ PanCan-d test in the US while maximizing our R&D productivity. This partnership with Proteomedix will combine leading proteomics-based researchers with state-of-the art capabilities from both companies to create an outstanding R&D platform,” said Philipp Mathieu – CEO and President, Immunovia.
In connection with the new R&D partnership, Linda Dexlin Mellby, Vice President Research & Development at Immunovia, will be leaving the company as of 4 November.
“Linda has been instrumental in the development of Immunovia’s IMMray™ PanCan-d test over the past nine years. We thank her for her many contributions to the company and wish her all the best in her future endeavors,” continued Philipp Mathieu – CEO and President, Immunovia.